Ultragenyx Pharmaceutical Inc. ( RARE) - Stock Earnings
RARE Upcoming earnings
Estimated EPS and revenue columns are available to paid members.
| Date | EPS (actual / est.) | Revenue low (est.) | Revenue (actual / est.) | Revenue high (est.) |
|---|---|---|---|---|
| Nov. 3, 2026, midnight | — / — | — | — / — | — |
RARE Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q4 | -129.0 million USD | 207.0 million USD |
| 2026Q1 | -185.0 million USD | 136.0 million USD |
| 2026Q2 | -92.0 million USD | 214.0 million USD |
| 2026Q4 Est. | — | — |
| 2027Q1 Est. | — | — |
| 2027Q2 Est. | — | — |
RARE Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -606.6 million USD | 434.2 million USD |
| 2024 | -569.2 million USD | 560.2 million USD |
| 2025 | -575.0 million USD | 673.0 million USD |
| 2026 Est. | — | — |
RARE
Price: $14.54
Earnings Per Share: -6.03 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 449700
Ebitda: -96.8 millionMarket Capitalization: 1.5 billion